Dengue Quadrivalent Vaccine rDENVΔ30,Live Attenuated
- Generic Name
- Dengue Quadrivalent Vaccine rDENVΔ30,Live Attenuated
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan-DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181-002)
- First Posted Date
- 2023-02-02
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- Butantan Institute
- Target Recruit Count
- 1364
- Registration Number
- NCT05710224
- Locations
- 🇧🇷
Hospital São Vicente de Paulo-Education and Research Management (Site 0007), Passo Fundo, Rio Grande Do Sul, Brazil
🇧🇷Hospital Escola da Universidade Federal de Pelotas (Site 0009), Pelotas, Rio Grande Do Sul, Brazil
🇧🇷Hospital Tacchini (Site 0006), Bento Gonçalves, Rio Grande Do Sul, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath